Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis

OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical care medicine 2007-04, Vol.35 (4), p.1061-1067
Hauptverfasser: Angus, Derek C, Yang, LiHong, Kong, Lan, Kellum, John A, Delude, Russell L, Tracey, Kevin J, Weissfeld, Lisa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1067
container_issue 4
container_start_page 1061
container_title Critical care medicine
container_volume 35
creator Angus, Derek C
Yang, LiHong
Kong, Lan
Kellum, John A
Delude, Russell L
Tracey, Kevin J
Weissfeld, Lisa
description OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors. DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP. SETTING:Twenty-eight U.S. teaching and community hospitals. PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls. INTERVENTIONS:None. MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis. CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis.
doi_str_mv 10.1097/01.CCM.0000259534.68873.2A
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70363732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70363732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</originalsourceid><addsrcrecordid>eNpNkd1uEzEQhVcIRNPCKyALCVQuNoz_1jF3IYIWqRU3cG3ZjpMYvPZi7zb0FXhqTBIpWBpZM_rmjGZO07zGMMcgxXvA89Xqfg71ES45ZfNusRB0TpZPmhnmFFogkj5tZgASWsokvWguS_kBgBkX9HlzgQWljLBu1vxZ-WynoEcft2jnt7u2T8YHPz6ibU7TgEz6jTC6vr2_-YjfIZuidXHMlU-xIJ0dcsE96NGtkY8VHndoijb1Q_D2UB2im_oUvUY6_p_tfUWLe3BVorih-PKiebbRobiXp_-q-f7507fVbXv39ebLannXWsbqPnVXgjHTcmOwEWujCd9oIx3hnIC0VguJDTGMO8mt7BYCc-iMNmtiOaeC0avm7VF3yOnX5Mqoel-sC0FHl6aiBNCOCkoq-OEI2pxKyW6jhux7nR8VBvXPCQVYVSfU2Ql1cEKRZW1-dZoymd6tz62n01fgzQnQxeqwyTpaX87coiOYSqgcO3L7FEaXy88w7V1WO6fDuDuMplWuJQACWM3aGhjoX9LRosE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70363732</pqid></control><display><type>article</type><title>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Angus, Derek C ; Yang, LiHong ; Kong, Lan ; Kellum, John A ; Delude, Russell L ; Tracey, Kevin J ; Weissfeld, Lisa</creator><creatorcontrib>Angus, Derek C ; Yang, LiHong ; Kong, Lan ; Kellum, John A ; Delude, Russell L ; Tracey, Kevin J ; Weissfeld, Lisa ; GenIMS Investigators</creatorcontrib><description>OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors. DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP. SETTING:Twenty-eight U.S. teaching and community hospitals. PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls. INTERVENTIONS:None. MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis. CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/01.CCM.0000259534.68873.2A</identifier><identifier>PMID: 17334246</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</publisher><subject>Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Community-Acquired Infections - blood ; Community-Acquired Infections - complications ; Emergency and intensive care: infection, septic shock ; Female ; HMGB1 Protein - blood ; Humans ; Immunoblotting ; Immunomodulators ; Intensive care medicine ; Intensive Care Units ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Pneumonia - blood ; Pneumonia - complications ; Pneumonia - physiopathology ; Prospective Studies ; Sepsis - blood ; Sepsis - complications ; Sepsis - physiopathology ; Severity of Illness Index</subject><ispartof>Critical care medicine, 2007-04, Vol.35 (4), p.1061-1067</ispartof><rights>2007 by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</citedby><cites>FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18621390$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17334246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Angus, Derek C</creatorcontrib><creatorcontrib>Yang, LiHong</creatorcontrib><creatorcontrib>Kong, Lan</creatorcontrib><creatorcontrib>Kellum, John A</creatorcontrib><creatorcontrib>Delude, Russell L</creatorcontrib><creatorcontrib>Tracey, Kevin J</creatorcontrib><creatorcontrib>Weissfeld, Lisa</creatorcontrib><creatorcontrib>GenIMS Investigators</creatorcontrib><title>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors. DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP. SETTING:Twenty-eight U.S. teaching and community hospitals. PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls. INTERVENTIONS:None. MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis. CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis.</description><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Community-Acquired Infections - blood</subject><subject>Community-Acquired Infections - complications</subject><subject>Emergency and intensive care: infection, septic shock</subject><subject>Female</subject><subject>HMGB1 Protein - blood</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Immunomodulators</subject><subject>Intensive care medicine</subject><subject>Intensive Care Units</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia - blood</subject><subject>Pneumonia - complications</subject><subject>Pneumonia - physiopathology</subject><subject>Prospective Studies</subject><subject>Sepsis - blood</subject><subject>Sepsis - complications</subject><subject>Sepsis - physiopathology</subject><subject>Severity of Illness Index</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkd1uEzEQhVcIRNPCKyALCVQuNoz_1jF3IYIWqRU3cG3ZjpMYvPZi7zb0FXhqTBIpWBpZM_rmjGZO07zGMMcgxXvA89Xqfg71ES45ZfNusRB0TpZPmhnmFFogkj5tZgASWsokvWguS_kBgBkX9HlzgQWljLBu1vxZ-WynoEcft2jnt7u2T8YHPz6ibU7TgEz6jTC6vr2_-YjfIZuidXHMlU-xIJ0dcsE96NGtkY8VHndoijb1Q_D2UB2im_oUvUY6_p_tfUWLe3BVorih-PKiebbRobiXp_-q-f7507fVbXv39ebLannXWsbqPnVXgjHTcmOwEWujCd9oIx3hnIC0VguJDTGMO8mt7BYCc-iMNmtiOaeC0avm7VF3yOnX5Mqoel-sC0FHl6aiBNCOCkoq-OEI2pxKyW6jhux7nR8VBvXPCQVYVSfU2Ql1cEKRZW1-dZoymd6tz62n01fgzQnQxeqwyTpaX87coiOYSqgcO3L7FEaXy88w7V1WO6fDuDuMplWuJQACWM3aGhjoX9LRosE</recordid><startdate>200704</startdate><enddate>200704</enddate><creator>Angus, Derek C</creator><creator>Yang, LiHong</creator><creator>Kong, Lan</creator><creator>Kellum, John A</creator><creator>Delude, Russell L</creator><creator>Tracey, Kevin J</creator><creator>Weissfeld, Lisa</creator><general>by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200704</creationdate><title>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</title><author>Angus, Derek C ; Yang, LiHong ; Kong, Lan ; Kellum, John A ; Delude, Russell L ; Tracey, Kevin J ; Weissfeld, Lisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4490-6882114a9fb1b7dba25fab9e255209cca791b2b45e95c96871506babd2c553743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Community-Acquired Infections - blood</topic><topic>Community-Acquired Infections - complications</topic><topic>Emergency and intensive care: infection, septic shock</topic><topic>Female</topic><topic>HMGB1 Protein - blood</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Immunomodulators</topic><topic>Intensive care medicine</topic><topic>Intensive Care Units</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia - blood</topic><topic>Pneumonia - complications</topic><topic>Pneumonia - physiopathology</topic><topic>Prospective Studies</topic><topic>Sepsis - blood</topic><topic>Sepsis - complications</topic><topic>Sepsis - physiopathology</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Angus, Derek C</creatorcontrib><creatorcontrib>Yang, LiHong</creatorcontrib><creatorcontrib>Kong, Lan</creatorcontrib><creatorcontrib>Kellum, John A</creatorcontrib><creatorcontrib>Delude, Russell L</creatorcontrib><creatorcontrib>Tracey, Kevin J</creatorcontrib><creatorcontrib>Weissfeld, Lisa</creatorcontrib><creatorcontrib>GenIMS Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Angus, Derek C</au><au>Yang, LiHong</au><au>Kong, Lan</au><au>Kellum, John A</au><au>Delude, Russell L</au><au>Tracey, Kevin J</au><au>Weissfeld, Lisa</au><aucorp>GenIMS Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2007-04</date><risdate>2007</risdate><volume>35</volume><issue>4</issue><spage>1061</spage><epage>1067</epage><pages>1061-1067</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>OBJECTIVE:High-mobility group box 1 (HMGB1) has been proposed as a late mediator of sepsis, but human data are sparse and conflicting. We describe plasma HMGB1 concentrations in humans with community-acquired pneumonia (CAP), the most common cause of severe sepsis, and test the hypotheses that HMGB1 levels are higher in CAP than healthy controls, higher in CAP with severe sepsis than CAP without severe sepsis, and higher in severe sepsis nonsurvivors than survivors. DESIGN:Random, outcome-stratified sample from a prospective study of 1,895 subjects hospitalized with CAP. SETTING:Twenty-eight U.S. teaching and community hospitals. PATIENTS:There were 122 CAP subjects (43 never developed severe sepsis, 49 developed severe sepsis and survived hospitalization, and 30 developed severe sepsis and died) and 38 healthy controls. INTERVENTIONS:None. MEASUREMENTS AND MAIN RESULTS:Median day of onset of severe sepsis was day of admission. HMGB1 was measured daily for the first week and analyzed using repeated-measures models with and without multivariable adjustment for baseline characteristics. HMGB1 concentrations were higher in CAP subjects compared with controls (median concentration on day of admission vs. controls, 190 vs. 0 ng/mL, p = .0001; 93.7% of all CAP measurements were elevated). HMGB1 remained elevated throughout the hospital course with no significant trend (p = .64) and did not differ between those with and without severe sepsis (p = .30). HMGB1 concentrations were higher in severe sepsis nonsurvivors than survivors (p = .001). HMGB1 concentrations remained elevated at discharge (median final HMGB1 measure, 176 ng/mL). Findings persisted in multivariable models and were robust to sensitivity analyses using alternative definitions of severe sepsis. CONCLUSIONS:HMGB1 is elevated in almost all CAP subjects, and higher circulating HMGB1 is associated with mortality. But immunodetectable HMGB1 levels were also persistently elevated in those patients who fared well. Thus, additional work is needed to understand the biological activities of serum HMGB1 in sepsis.</abstract><cop>Hagerstown, MD</cop><pub>by the Society of Critical Care Medicine and Lippincott Williams &amp; Wilkins</pub><pmid>17334246</pmid><doi>10.1097/01.CCM.0000259534.68873.2A</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-3493
ispartof Critical care medicine, 2007-04, Vol.35 (4), p.1061-1067
issn 0090-3493
1530-0293
language eng
recordid cdi_proquest_miscellaneous_70363732
source MEDLINE; Journals@Ovid Ovid Autoload
subjects Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Community-Acquired Infections - blood
Community-Acquired Infections - complications
Emergency and intensive care: infection, septic shock
Female
HMGB1 Protein - blood
Humans
Immunoblotting
Immunomodulators
Intensive care medicine
Intensive Care Units
Male
Medical sciences
Pharmacology. Drug treatments
Pneumonia - blood
Pneumonia - complications
Pneumonia - physiopathology
Prospective Studies
Sepsis - blood
Sepsis - complications
Sepsis - physiopathology
Severity of Illness Index
title Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A50%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20high-mobility%20group%20box%201%20(HMGB1)%20concentrations%20are%20elevated%20in%20both%20uncomplicated%20pneumonia%20and%20pneumonia%20with%20severe%20sepsis&rft.jtitle=Critical%20care%20medicine&rft.au=Angus,%20Derek%20C&rft.aucorp=GenIMS%20Investigators&rft.date=2007-04&rft.volume=35&rft.issue=4&rft.spage=1061&rft.epage=1067&rft.pages=1061-1067&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/01.CCM.0000259534.68873.2A&rft_dat=%3Cproquest_cross%3E70363732%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70363732&rft_id=info:pmid/17334246&rfr_iscdi=true